In this work, we observe significant ERBB2 mutational heterogeneity in patients with urothelial cancer, including discordance in ERBB2 mutational status between primary and metastatic tumors sites, as well as discordance of a subset of patient-derived models and the urothelial tumors from which they were derived. Here, ERBB2 is linked to metastatic neoplasm.